No Data
No Data
Stifel Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $22
Stifel Nicolaus Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum IT Partners Announces Acquisition of Fortress Security Risk Management
Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know
Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know
No Data
Lnova : still!